What is the 13F Pro Quality Score for WVE?

13F Pro ranks Wave Life Sciences Ltd. (WVE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WVE's current score at https://13fpro.ai/research/WVE (free sign-up required for the full ranking).

Which hedge funds own the most WVE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of WVE include RA CAPITAL MANAGEMENT, L.P., GSK plc, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/WVE as soon as new 13F filings post.

Where does 13F Pro source WVE data?

All Wave Life Sciences Ltd. fundamentals and ownership data come directly from SEC EDGAR. Wave Life Sciences Ltd. files with the SEC under CIK 1631574. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WVE in?

Wave Life Sciences Ltd. (WVE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is WVE research updated on 13F Pro?

WVE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Wave Life Sciences Ltd.(WVE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1631574 WVE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

WVE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Wave Life Sciences Ltd. (WVE), a Healthcare sector company. WVE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Wave Life Sciences Ltd. reports quarterly revenue of $38.2M, net income of $-26.1M, free cash flow of $-60.0M. Top institutional holders of WVE by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., GSK plc, BlackRock,, based on the most recent SEC filings. WVE trades on the Nasdaq exchange and files with the SEC under CIK 1631574. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WVE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Wave Life Sciences Ltd. directly from SEC EDGAR. Wave Life Sciences Ltd.'s 13F Pro composite quality score has ranged between 9 and 27 since 2021, currently 20.4 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q1 2026

$38.2M

Net Income

Q1 2026

$-26.1M

Free Cash Flow

Q1 2026

$-60.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-60.5% YoY

$42.7MFY 2025

FY21 $41.0MFY23 $113.3MFY24 $108.3MFY25 $42.7M

Net Income

-110.7% YoY

$-204.4MFY 2025

FY21 $-122.2MFY23 $-57.5MFY24 $-97.0MFY25 $-204.4M

Operating Income

-95.1% YoY

$-215.4MFY 2025

FY21 $-127.0MFY23 $-68.0MFY24 $-110.4MFY25 $-215.4M

EPS (Diluted)

-72.9% YoY

$-1.21FY 2025

FY21 $-2.36FY23 $-0.54FY24 $-0.70FY25 $-1.21

Total Assets

+81.3% YoY

$638.5MFY 2025

FY21 $207.0MFY23 $274.9MFY24 $352.2MFY25 $638.5M

Op. Cash Flow

-24.1% YoY

$-187.5MFY 2025

FY21 $-89.0MFY23 $-19.4MFY24 $-151.0MFY25 $-187.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$42.7M -60.5%	$108.3M -4.4%	$113.3M +176.6%	$41.0M +104.0%	$20.1M +25.6%	$16.0M
Net Income	$-204.4M -110.7%	$-97.0M -68.7%	$-57.5M +53.0%	$-122.2M +18.5%	$-149.9M +22.6%	$-193.6M
Operating Income	$-215.4M -95.1%	$-110.4M -62.4%	$-68.0M +46.5%	$-127.0M +17.2%	$-153.4M +26.4%	$-208.3M
EPS (Diluted)	$-1.21 -72.9%	$-0.70 -29.6%	$-0.54 +77.1%	$-2.36	—	—
Total Assets	$638.5M +81.3%	$352.2M +28.1%	$274.9M +32.8%	$207.0M -25.9%	$279.2M -1.8%	$284.3M
Operating Cash Flow	$-187.5M -24.1%	$-151.0M -677.2%	$-19.4M +78.2%	$-89.0M +23.3%	$-116.0M +38.4%	$-188.2M

AI Insight: WVE Financial Trends

Revenue surged from $9M in Q2 2025 to $38M in Q1 2026, while net losses narrowed from $-54M to $-26M despite equity dilution.

• Revenue jumped from $9M in Q2 2025 to $38M in Q1 2026, a 322% increase.

• Net losses improved from $-54M in Q3 2025 to $-26M in Q1 2026.

• Operating losses narrowed from $-56M in Q4 2025 to $-31M in Q1 2026.

• Equity increased dramatically from $125M in Q3 2025 to $518M in Q4 2025.

⚠ Operating cash flow deteriorated from $-34M in Q4 2025 to $-60M in Q1 2026.

⚠ Revenue remains sporadic with no consistent quarterly pattern across periods.

AI Insight: WVE Ratio Trends

Wave Life Sciences shows improving profitability metrics with ROE recovering from -173.0% in Q3 2025 to -20.4% in Q1 2026.

• ROE improved dramatically from -173.0% in Q3 2025 to -20.4% in Q1 2026, marking consistent recovery over two quarters.

• ROA strengthened from -89.2% in Q3 2025 to -17.9% in Q1 2026, indicating better asset utilization efficiency.

• Operating margin of -81.8% in Q1 2026 shows the company remains deeply unprofitable operationally.

⚠ ROIC volatility with swings from 43.9% in Q4 2024 to -43.6% in Q4 2025 suggests unstable capital efficiency.

⚠ Sparse financial data across quarters limits visibility into operational consistency and underlying business trends.

Get alerted when WVE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Wave Life Sciences Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WVE

RA CAPITAL MANAGEMENT, L.P.
$195.6M26,975,505 sh
GSK plc
$132.3M18,245,691 sh
BlackRock, Inc.
$102.4M14,117,412 sh
MAVERICK CAPITAL LTD
$73.7M10,161,399 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$39.4M5,431,021 sh
FEDERATED HERMES, INC.
$38.6M5,317,457 sh
FMR LLC
$37.6M5,192,761 sh
683 Capital Management, LLC
$35.5M4,900,000 sh
PRIMECAP MANAGEMENT CO/CA/
$35.0M4,832,952 sh
M28 Capital Management LP
$33.3M4,588,284 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$195.6M	26,975,505
GSK plc	$132.3M	18,245,691
BlackRock, Inc.	$102.4M	14,117,412
MAVERICK CAPITAL LTD	$73.7M	10,161,399
DRIEHAUS CAPITAL MANAGEMENT LLC	$39.4M	5,431,021
FEDERATED HERMES, INC.	$38.6M	5,317,457
FMR LLC	$37.6M	5,192,761
683 Capital Management, LLC	$35.5M	4,900,000
PRIMECAP MANAGEMENT CO/CA/	$35.0M	4,832,952
M28 Capital Management LP	$33.3M	4,588,284

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WVE on your watchlist

Track score changes the day Wave Life Sciences Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WVE a good stock to buy?

13F Pro's AI-powered analysis of Wave Life Sciences Ltd. (WVE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WVE are available on the WVE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own WVE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WVE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Wave Life Sciences Ltd.'s investment landscape.